Drug Utilization Review: Boxed Warning for Benzodiazepine Medications

Winter 2020

pills spilling out of a bottle

According to the Department of Health Care Services monthly Drug Utilization Review, on September 23, 2020, the Food and Drug Administration (FDA) required an update of the boxed warning for all benzodiazepine medications. The update addresses the serious risks of abuse, addiction, physical dependence and withdrawal reactions. Benzodiazepines are commonly indicated to treat conditions such as anxiety, insomnia and seizures. However, even taken at recommended dosages, their use can lead to misuse, abuse and addiction. 

Risks increase when benzodiazepines are used with alcohol, opioids and illicit drugs. When taken consistently for several days or weeks, physical dependence can occur. Suddenly stopping benzodiazepine use or reducing the dose too quickly can result in serious withdrawal reactions, including seizures, which can be life-threatening. The FDA is also requiring updates to the existing patient Medication Guides to provide further education to patients and caregivers.